Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 1/20 | 0.69 |
| ▸ | FLT3 | P36888 | 1/20 | 0.69 |
| ▸ | EGFR | P00533 | 4/20 | 0.50 |
| ▸ | VCP | P55072 | 5/20 | 0.46 |
| ▸ | KDR | P35968 | 3/20 | 0.45 |
| ▸ | FLT1 | P17948 | 3/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.39 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.38 |
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | BCR | P11274 | 1/20 | 0.37 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL27909280 | 0.91 | FGFR2 (0.58) | FGFR2FLT3EGFRVCPKDR | |
| SCHEMBL1642784 | 0.88 | FGFR2 (0.54) | FGFR2FLT3EGFRVCPKDR | |
| SCHEMBL1640855 | 0.84 | FGFR2 (0.50) | FGFR2FLT3EGFRVCPKDR | |
| Akn-028 SCHEMBL31060922 | 0.82 | FGFR2 (1.00) | FGFR2FLT3EGFRKDRFLT1 | |
| SCHEMBL1642794 | 0.82 | FGFR2 (0.72) | FGFR2FLT3EGFRFLT1ROCK2 | |
| Akn-028 SCHEMBL1642669 | 0.82 | FGFR2 (1.00) | FGFR2FLT3EGFRKDRFLT1 | |
| SCHEMBL1642894 | 0.81 | EGFR (0.56) | FGFR2FLT3EGFRVCPKDR | |
| Trifluoroacetic Acid SCHEMBL27927102 | 0.81 | ATR (0.49) | FGFR2FLT3VCPKDRCDK1 | |
| SCHEMBL8544057 | 0.72 | EGFR (0.48) | EGFRVCPKDRFLT1SYK | |
| SCHEMBL1642621 | 0.71 | FGFR2 (0.81) | FGFR2FLT3EGFRKDRFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2671876-A2 | Pyrazine derivatives and their use as protein kinase inhbitors | Akinion Pharmaceuticals AB (SE) | 2013-12-11 | — | — | EP | claimed |
| US-20130203774-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | AKINION PHARMACEUTICALS AB (SE) | 2013-08-08 | — | — | US | claimed |
| US-20110098310-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | BIOVITRUM AB (SE) | 2011-04-28 | — | — | US | claimed |
| JP-2011510948-A | — | — | 2011-04-07 | — | — | JP | claimed |
| EP-2252597-A2 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | Akinion Pharmaceuticals AB (SE) | 2010-11-24 | — | — | EP | claimed |
| WO-2009095399-A2 | PYRAZINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHBITORS | AKINION PHARMACEUTICALS AB (SE) | 2009-08-06 | — | — | WO | claimed |
| EP-2671876-A2 | Pyrazine derivatives and their use as protein kinase inhbitors | Akinion Pharmaceuticals AB (SE) | 2013-12-11 | — | — | EP | disclosed |
| US-20130203774-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | AKINION PHARMACEUTICALS AB (SE) | 2013-08-08 | — | — | US | disclosed |
| US-20130203774-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | AKINION PHARMACEUTICALS AB (SE) | 2013-08-08 | — | — | US | disclosed |
| US-20130203774-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | AKINION PHARMACEUTICALS AB (SE) | 2013-08-08 | — | — | US | disclosed |
| CN-101970418-B | Pyrazine derivative and its uses as protein kinase inhibitor | AKINION PHARMACEUTICALS AB | 2013-07-03 | — | — | CN | disclosed |
| US-8436171-B2 | Amino substituted pyrazines as inhibitors or protein kinases | AKINION PHARMACEUTICALS AB (SE) | 2013-05-07 | — | — | US | disclosed |
| US-8436171-B2 | Amino substituted pyrazines as inhibitors or protein kinases | AKINION PHARMACEUTICALS AB (SE) | 2013-05-07 | — | — | US | disclosed |
| US-20110098310-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | BIOVITRUM AB (SE) | 2011-04-28 | — | — | US | disclosed |
| US-20110098310-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | BIOVITRUM AB (SE) | 2011-04-28 | — | — | US | disclosed |
| US-20110098310-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | BIOVITRUM AB (SE) | 2011-04-28 | — | — | US | disclosed |
| CN-101970418-A | Novel compounds, use and preparation thereof | AKINION PHARMACEUTICALS AB | 2011-02-09 | — | — | CN | disclosed |
| EP-2252597-A2 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | Akinion Pharmaceuticals AB (SE) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009095399-A2 | PYRAZINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHBITORS | AKINION PHARMACEUTICALS AB (SE) | 2009-08-06 | — | — | WO | disclosed |
| WO-2009095399-A2 | PYRAZINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHBITORS | AKINION PHARMACEUTICALS AB (SE) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203774-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | FLT3, MLLT1, MYD88 | FGFR2 329/4885FLT3 1/4885EGFR 298/4885 |
| US-20110098310-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | FLT3, MLLT1, MYD88 | FGFR2 329/4885FLT3 1/4885EGFR 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.